Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 8/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303982 | 0.84 | CYP17A1 (0.56) | MKNK1MKNK2CCR1NR3C1CYP17A1 | |
| SCHEMBL441916 | 0.82 | CCR1 (0.46) | CCR1NR3C1CYP17A1CYP1A2PGR | |
| SCHEMBL443252 | 0.82 | CCR1 (0.46) | MKNK1MKNK2CCR1NR3C1CYP17A1 | |
| SCHEMBL1255335 | 0.78 | CCR1 (0.58) | CCR1NR3C1CYP11B2 | |
| SCHEMBL476793 | 0.78 | CYP1A2 (0.51) | MKNK1MKNK2CYP17A1CYP1A2MAPT | |
| SCHEMBL4573821 | 0.78 | MAPK14 (0.50) | MKNK1MKNK2CCR1NR3C1CYP17A1 | |
| SCHEMBL4573040 | 0.77 | CCR1 (0.45) | CCR1NR3C1CYP17A1CYP1A2MAPT | |
| SCHEMBL25257558 | 0.77 | XDH (0.53) | MKNK1MKNK2CCR1NR3C1CYP17A1 | |
| SCHEMBL30491768 | 0.77 | XDH (0.53) | MKNK1MKNK2CCR1NR3C1CYP17A1 | |
| SCHEMBL4878604 | 0.77 | MAPT (0.46) | MKNK1MKNK2CCR1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008055710-A1 | INDOLE AND INDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055709-A1 | INDAZOLE AND INDOLE DERIVATIVES AS ANTI -INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921067-A1 | Indole and indazole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921068-A1 | Indazole and indole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008052808-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1917963-A1 | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGIS, PTGS1, PTGES | MKNK1 1981/4885MKNK2 1850/4885CCR1 347/4885 |
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | IDO1, IL1B, IDO2 | MKNK1 1380/4885MKNK2 1120/4885CCR1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.